Home › Funds › New Vernon Capital Holdings II LLC › CPRX
New Vernon Capital Holdings II LLC position in CPRX
CATALYST PHARMACEUTICALS INC
New Vernon Capital Holdings II LLC reported holding 13,521 shares of CPRX (CATALYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$425K, representing 0.23% of its reported portfolio and ranking #25 among its reported holdings. New Vernon Capital Holdings II LLC has disclosed CPRX holdings in 9 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How New Vernon Capital Holdings II LLC's CPRX position evolved
New Vernon Capital Holdings II LLC first disclosed a stake in CPRX in Q1 2024 at 7,864 shares (US$125K). The position peaked in Q1 2025 at 327,860 shares, worth US$13.5M. Across 9 filings, New Vernon Capital Holdings II LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 13,521 shares valued at US$425K. Notable position changes include a 5531% increase in Q1 2025, a 96% trim in Q2 2025.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 7.86K | $125.35K | New |
| Q2 2024 | 7.86K | $121.81K | Hold |
| Q4 2024 | 5.82K | $121.50K | New |
| Q1 2025 | 327.86K | $13.52M | Add |
| Q2 2025 | 13.52K | $293.38K | Reduce |
| Q3 2025 | 13.52K | $266.34K | Hold |
| Q4 2025 | 13.52K | $315.56K | Hold |
| Q1 2026 | 13.52K | $334.75K | Hold |
| Q2 2026 | 13.52K | $424.96K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CPRX and 13F data
CPRX (CATALYST PHARMACEUTICALS INC) is a company whose sector is not yet classified in our data. 43 other funds we track also report a position in CPRX — the largest reported positions include GLAZER CAPITAL, LLC (US$113.2M), HBK INVESTMENTS L P (US$88.6M), NEXPOINT ASSET MANAGEMENT, L.P. (US$50.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CPRX
- GLAZER CAPITAL, LLC 3.60M sh · $113.24M · Q2 2026
- HBK INVESTMENTS L P 2.82M sh · $88.64M · Q2 2026
- NEXPOINT ASSET MANAGEMENT, L.P. 1.60M sh · $50.37M · Q2 2026
- Polar Asset Management Partners Inc. 1.15M sh · $36.15M · Q2 2026
- WATER ISLAND CAPITAL LLC 933.82K sh · $29.35M · Q2 2026
- KENNEDY CAPITAL MANAGEMENT LLC 856.61K sh · $26.92M · Q2 2026
- Sagefield Capital LP 569.48K sh · $17.90M · Q2 2026
More on New Vernon Capital Holdings II LLC
FAQ
How long has New Vernon Capital Holdings II LLC held CPRX?
New Vernon Capital Holdings II LLC has disclosed CPRX holdings in 9 of the last 10 reported quarters, going back to Q1 2024.
What is New Vernon Capital Holdings II LLC's current position in CPRX?
As of Q2 2026, New Vernon Capital Holdings II LLC holds 13.52K shares of CPRX (CATALYST PHARMACEUTICALS INC), valued at $424.96K, representing 0.23% of its reported portfolio and ranking #25.
Has New Vernon Capital Holdings II LLC been buying or selling CPRX?
In the latest 13F filing (Q2 2026), New Vernon Capital Holdings II LLC held unchanged its position in CPRX. The position peaked in Q1 2025 at 327.86K shares.
Which other funds hold CPRX?
Other major institutional holders of CPRX include GLAZER CAPITAL, LLC, HBK INVESTMENTS L P, NEXPOINT ASSET MANAGEMENT, L.P., among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.